Amr Seif introduces the evolution in Astellas' MEA strategy; the adoption of innovative access models to ensure that the companies' therapies are available for all patients who need them; and the challenges and opportunities in the Saudi pharma market.
We are opening a new chapter in medicine. The early 2000s were focused on monoclonal antibodies, 2015 to 2025 is all about immune therapy, but 2025 and beyond will be the era of cell and gene therapies
Mohamed Mazen Batterjee, managing director of Batterjee Pharma, explains how he has turned the business around since joining in 2014, the interplay between the firm’s contract and proprietary manufacturing operations,…
IQVIA Vice President and General Manager Saudi Arabia & Egypt Mohamed Mostafa gives his expert insights into the transformation of the Saudi pharma market in recent years, covering everything from…
Mecomed is the largest medical devices, imaging, and diagnostics trade association in the Middle East and Africa (MEA). Rami Rajab, chairman, highlights the role of the association in shaping the…
Saudi Chemical Company Holding (SCCH), Saudi Arabia’s leading manufacturer of civil and military explosives, has been expanding its pharma sector footprint in recent years. Today, the company has capabilities across…
Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma…
While Saudi Arabia is becoming an increasingly attractive investment destination for global pharma, some stakeholders continue to have concerns about whether the country’s intellectual property (IP) protection system is truly…
See our Cookie Privacy Policy Here